Savran Technologies is developing non-invasive diagnostics based on capture and analysis of rare cells. Savran Technologies has developed and completed initial testing of a novel liquid biopsy technology. Savran Tech has overcome the challenge of utilizing cell-based liquid biopsy. Cells offer significant advantages over cell-free DNA in diagnostics — for example, they provide access to the entire genome; can provide transcriptional and functional information; can differentiate between primary tumor and metastases; can be cultured for drug screening; and can offer insights into tumor heterogeneity.